Production of SARS-CoV-2 Pseudotyped Viral Particles for the Evaluation of New Therapies Against COVID-19. FAVET 2022, 20 (Suppl.), 44-50. https://doi.org/10.14409/favecv.2021.Suppl. 44-50.